schliessen

Filtern

 

Bibliotheken

Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls

The association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and breast cancer risk has been widely reported, but results were inconsistent and underpowered. To clarify the effects of MTHFR polymorphisms on the risk of breast cancer, an updated meta-analysis of all availabl... Full description

Journal Title: Breast Cancer Research and Treatment 2010, Vol.123(2), pp.499-506
Main Author: Qi, Xiaowei
Other Authors: Ma, Xiangyu , Yang, Xinhua , Fan, Linjun , Zhang, Yi , Zhang, Fan , Chen, Li , Zhou, Yan , Jiang, Jun
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0167-6806 ; E-ISSN: 1573-7217 ; DOI: 10.1007/s10549-010-0773-7
Link: http://dx.doi.org/10.1007/s10549-010-0773-7
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: springer_jour10.1007/s10549-010-0773-7
title: Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls
format: Article
creator:
  • Qi, Xiaowei
  • Ma, Xiangyu
  • Yang, Xinhua
  • Fan, Linjun
  • Zhang, Yi
  • Zhang, Fan
  • Chen, Li
  • Zhou, Yan
  • Jiang, Jun
subjects:
  • Methylenetetrahydrofolate reductase
  • Folate
  • One carbon metabolism
  • Polymorphism
  • Breast cancer
  • Meta-analysis
ispartof: Breast Cancer Research and Treatment, 2010, Vol.123(2), pp.499-506
description: The association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and breast cancer risk has been widely reported, but results were inconsistent and underpowered. To clarify the effects of MTHFR polymorphisms on the risk of breast cancer, an updated meta-analysis of all available studies relating C677T and/or A1298C polymorphisms of MTHFR gene to the risk of breast cancer was conducted. Eligible articles were identified by search of databases including MEDLINE, PubMed, Web of Science, EMBASE and Chinese Biomedical Literature database (CBM) for the period up to January 2010. Finally, a total of 41 studies with 16,480 cases and 22,388 controls were included, all for C677T polymorphism and 20 with 12,170 cases and 15,865 controls for A1298C polymorphism. The pooled ORs were performed for the allele contrasts, additive genetic model, dominant genetic model, and recessive genetic model, respectively. Subgroup analyses were also performed by ethnicity and menopausal status. With respect to C677T polymorphism, significantly elevated breast cancer risk was found in overall analysis (T vs. C: OR = 1.041, 95% CI = 1.009–1.073; TT vs. CC: OR = 1.132, 95% CI = 1.019–1.259; TT vs. CC + CT: OR = 1.119, 95% CI = 1.014–1.236); in the subgroup analysis by ethnicity, significantly increased risk was found in East Asian population (T vs. C: OR = 1.121, 95% CI = 1.016–1.237; TT vs. CC: OR = 1.331, 95% CI = 1.073–1.650; TT vs. CC + CT: OR = 1.265, 95% CI = 1.058–1.513) but not in Caucasian population; in the subgroup analysis by menopausal status, no statistically significant association was found. With respect to A1298C polymorphism, no significant association with breast cancer risk was demonstrated in overall, ethnicity- and menopausal status-based population. It can be concluded that potentially functional MTHFR C677T polymorphism may play a low penetrance role in the development of breast cancer.
language: eng
source:
identifier: ISSN: 0167-6806 ; E-ISSN: 1573-7217 ; DOI: 10.1007/s10549-010-0773-7
fulltext: fulltext
issn:
  • 1573-7217
  • 15737217
  • 0167-6806
  • 01676806
url: Link


@attributes
ID117873003
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1007/s10549-010-0773-7
sourceidspringer_jour
recordidTN_springer_jour10.1007/s10549-010-0773-7
sourcesystemPC
pqid746316868
galeid356447077
display
typearticle
titleMethylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls
creatorQi, Xiaowei ; Ma, Xiangyu ; Yang, Xinhua ; Fan, Linjun ; Zhang, Yi ; Zhang, Fan ; Chen, Li ; Zhou, Yan ; Jiang, Jun
ispartofBreast Cancer Research and Treatment, 2010, Vol.123(2), pp.499-506
identifier
subjectMethylenetetrahydrofolate reductase ; Folate ; One carbon metabolism ; Polymorphism ; Breast cancer ; Meta-analysis
descriptionThe association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and breast cancer risk has been widely reported, but results were inconsistent and underpowered. To clarify the effects of MTHFR polymorphisms on the risk of breast cancer, an updated meta-analysis of all available studies relating C677T and/or A1298C polymorphisms of MTHFR gene to the risk of breast cancer was conducted. Eligible articles were identified by search of databases including MEDLINE, PubMed, Web of Science, EMBASE and Chinese Biomedical Literature database (CBM) for the period up to January 2010. Finally, a total of 41 studies with 16,480 cases and 22,388 controls were included, all for C677T polymorphism and 20 with 12,170 cases and 15,865 controls for A1298C polymorphism. The pooled ORs were performed for the allele contrasts, additive genetic model, dominant genetic model, and recessive genetic model, respectively. Subgroup analyses were also performed by ethnicity and menopausal status. With respect to C677T polymorphism, significantly elevated breast cancer risk was found in overall analysis (T vs. C: OR = 1.041, 95% CI = 1.009–1.073; TT vs. CC: OR = 1.132, 95% CI = 1.019–1.259; TT vs. CC + CT: OR = 1.119, 95% CI = 1.014–1.236); in the subgroup analysis by ethnicity, significantly increased risk was found in East Asian population (T vs. C: OR = 1.121, 95% CI = 1.016–1.237; TT vs. CC: OR = 1.331, 95% CI = 1.073–1.650; TT vs. CC + CT: OR = 1.265, 95% CI = 1.058–1.513) but not in Caucasian population; in the subgroup analysis by menopausal status, no statistically significant association was found. With respect to A1298C polymorphism, no significant association with breast cancer risk was demonstrated in overall, ethnicity- and menopausal status-based population. It can be concluded that potentially functional MTHFR C677T polymorphism may play a low penetrance role in the development of breast cancer.
languageeng
source
version9
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://dx.doi.org/10.1007/s10549-010-0773-7$$EView_full_text_in_Springer_(Subscribers_only)
search
creatorcontrib
0Qi, Xiaowei
1Ma, Xiangyu
2Yang, Xinhua
3Fan, Linjun
4Zhang, Yi
5Zhang, Fan
6Chen, Li
7Zhou, Yan
8Jiang, Jun
titleMethylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls
descriptionThe association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and breast cancer risk has been widely reported, but results were inconsistent and underpowered. To clarify the effects of MTHFR polymorphisms on the risk of breast cancer, an updated meta-analysis of all available studies relating C677T and/or A1298C polymorphisms of MTHFR gene to the risk of breast cancer was conducted. Eligible articles were identified by search of databases including MEDLINE, PubMed, Web of Science, EMBASE and Chinese Biomedical Literature database (CBM) for the period up to January 2010. Finally, a total of 41 studies with 16,480 cases and 22,388 controls were included, all for C677T polymorphism and 20 with 12,170 cases and 15,865 controls for A1298C polymorphism. The pooled ORs were performed for the allele contrasts, additive genetic model, dominant genetic model, and recessive genetic model, respectively. Subgroup analyses were also performed by ethnicity and menopausal status. With respect to C677T polymorphism, significantly elevated breast cancer risk was found in overall analysis (T vs. C: OR = 1.041, 95% CI = 1.009–1.073; TT vs. CC: OR = 1.132, 95% CI = 1.019–1.259; TT vs. CC + CT: OR = 1.119, 95% CI = 1.014–1.236); in the subgroup analysis by ethnicity, significantly increased risk was found in East Asian population (T vs. C: OR = 1.121, 95% CI = 1.016–1.237; TT vs. CC: OR = 1.331, 95% CI = 1.073–1.650; TT vs. CC + CT: OR = 1.265, 95% CI = 1.058–1.513) but not in Caucasian population; in the subgroup analysis by menopausal status, no statistically significant association was found. With respect to A1298C polymorphism, no significant association with breast cancer risk was demonstrated in overall, ethnicity- and menopausal status-based population. It can be concluded that potentially functional MTHFR C677T polymorphism may play a low penetrance role in the development of breast cancer.
subject
0Methylenetetrahydrofolate reductase
1Folate
2One carbon metabolism
3Polymorphism
4Breast cancer
5Meta-analysis
general
010.1007/s10549-010-0773-7
1English
2Springer Science & Business Media B.V.
3SpringerLink
sourceidspringer_jour
recordidspringer_jour10.1007/s10549-010-0773-7
issn
01573-7217
115737217
20167-6806
301676806
rsrctypearticle
creationdate2010
addtitle
0Breast Cancer Research and Treatment
1Breast Cancer Res Treat
searchscopespringer_journals_complete
scopespringer_journals_complete
lsr30VSR-Enriched:[galeid, pages, pqid]
sort
titleMethylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls
authorQi, Xiaowei ; Ma, Xiangyu ; Yang, Xinhua ; Fan, Linjun ; Zhang, Yi ; Zhang, Fan ; Chen, Li ; Zhou, Yan ; Jiang, Jun
creationdate20100900
facets
frbrgroupid4710491804399522871
frbrtype5
languageeng
creationdate2010
topic
0Methylenetetrahydrofolate Reductase
1Folate
2One Carbon Metabolism
3Polymorphism
4Breast Cancer
5Meta-Analysis
collectionSpringerLink
prefilterarticles
rsrctypearticles
creatorcontrib
0Qi, Xiaowei
1Ma, Xiangyu
2Yang, Xinhua
3Fan, Linjun
4Zhang, Yi
5Zhang, Fan
6Chen, Li
7Zhou, Yan
8Jiang, Jun
jtitleBreast Cancer Research And Treatment
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Qi
1Ma
2Yang
3Fan
4Zhang
5Chen
6Zhou
7Jiang
aufirst
0Xiaowei
1Xiangyu
2Xinhua
3Linjun
4Yi
5Fan
6Li
7Yan
8Jun
au
0Qi, Xiaowei
1Ma, Xiangyu
2Yang, Xinhua
3Fan, Linjun
4Zhang, Yi
5Zhang, Fan
6Chen, Li
7Zhou, Yan
8Jiang, Jun
atitleMethylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls
jtitleBreast Cancer Research and Treatment
stitleBreast Cancer Res Treat
risdate201009
volume123
issue2
spage499
epage506
issn0167-6806
eissn1573-7217
genrearticle
ristypeJOUR
abstractThe association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and breast cancer risk has been widely reported, but results were inconsistent and underpowered. To clarify the effects of MTHFR polymorphisms on the risk of breast cancer, an updated meta-analysis of all available studies relating C677T and/or A1298C polymorphisms of MTHFR gene to the risk of breast cancer was conducted. Eligible articles were identified by search of databases including MEDLINE, PubMed, Web of Science, EMBASE and Chinese Biomedical Literature database (CBM) for the period up to January 2010. Finally, a total of 41 studies with 16,480 cases and 22,388 controls were included, all for C677T polymorphism and 20 with 12,170 cases and 15,865 controls for A1298C polymorphism. The pooled ORs were performed for the allele contrasts, additive genetic model, dominant genetic model, and recessive genetic model, respectively. Subgroup analyses were also performed by ethnicity and menopausal status. With respect to C677T polymorphism, significantly elevated breast cancer risk was found in overall analysis (T vs. C: OR = 1.041, 95% CI = 1.009–1.073; TT vs. CC: OR = 1.132, 95% CI = 1.019–1.259; TT vs. CC + CT: OR = 1.119, 95% CI = 1.014–1.236); in the subgroup analysis by ethnicity, significantly increased risk was found in East Asian population (T vs. C: OR = 1.121, 95% CI = 1.016–1.237; TT vs. CC: OR = 1.331, 95% CI = 1.073–1.650; TT vs. CC + CT: OR = 1.265, 95% CI = 1.058–1.513) but not in Caucasian population; in the subgroup analysis by menopausal status, no statistically significant association was found. With respect to A1298C polymorphism, no significant association with breast cancer risk was demonstrated in overall, ethnicity- and menopausal status-based population. It can be concluded that potentially functional MTHFR C677T polymorphism may play a low penetrance role in the development of breast cancer.
copBoston
pubSpringer US
doi10.1007/s10549-010-0773-7
pages499-506
date2010-09